pocketful logo
Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE BSE: 532321

900

(2.31)%

Tue, 03 Feb 2026, 07:06 am

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    88473.12

  • Net Profit

    4614.80

  • P/B

    3.72

  • Sector P/E

    31.51

  • P/E

    19.69

  • EV/EBITDA

    12.57

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    16.31

  • ROCE (Industry)

    15.98

  • RONW (Industry)

    14.01

  • ROE

    21.08

  • ROCE

    24.56

  • Debt/Equity

    0.09

  • EPS (TTM)

    50.03

  • Dividend Yield

    1.25

  • Book Value

    251.45

  • Interest Cover

    37.33

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (3.5x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (4.8x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Cadila Healthcare's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
thumbs up icon

Cons

  • Cadila Healthcare's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Cadila Healthcare is expected to decrease over the next 2 years.
  • Cadila Healthcare's net income is expected to increase but not above the 50% threshold in 2 years time.
  • Cadila Healthcare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
  • Cadila Healthcare's revenue is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters75.0074.9974.9974.9974.98
FII7.067.347.137.327.53
DII11.0910.8611.1311.0110.65
Public6.856.806.746.686.84
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

51.58

MACD

-7.40

50 DMA

910.89

200 DMA

950.17

Support and Resistance

TypeR1R2R3PPS1S2S3
Classic1064.18979.13932.22894.08847.17809.03723.98
Fibonacci979.13946.64926.57894.08861.59841.52809.03
Camarilla908.69900.89893.10894.08877.50869.71861.91

Pivots Level: Classic

R3

+170.10

1064.18

R2

+85.05

979.13

R1

+38.13

932.22

894.08
894.08
Pivot Point
LTP: 900

S1

-46.92

847.17

S2

-85.05

809.03

S3

-170.10

723.98

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    888.22

  • 20-EMA

    892.61

  • 30-EMA

    898.64

  • 50-EMA

    910.88

  • 100-EMA

    931.08

  • 200-EMA

    944.89

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
06 Nov 2025board-meetingsQuarterly Results
20 May 2025agm
19 May 2025dividend₹11.00 Dividend /Share25 Jul 2025
17 May 2024dividend₹3.00 Dividend /Share26 Jul 2024
17 May 2024agm
09 Feb 2024buyback
18 May 2023dividend₹6.00 Dividend /Share28 Jul 2023
18 May 2023agm
05 Dec 2022egm
20 May 2022dividend₹2.50 Dividend /Share29 Jul 2022

Read More

Peer Comparison

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

About Zydus Lifesciences Ltd

Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.(Source : 202503-Annual Report Page No:291)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

Pankaj R Patel

Employees

Contact

Website icon

Website

http://www.zyduscadila.com

Email icon

Email

dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.

Phone icon

Phone

91-079-26868100

Location icon

Location

Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W, Ahmedabad, Gujarat, 382481

Read More

zydus lifesciences ltd History

YearHistory
2020
  • Zydus and CMS entered pact for Desidustat in Greater China.
  • Zydus Wellness launched hand sanitizer under Nycil brand.
  • Zydus Cadila launched COVID-19 drug Remdesivir in India.
  • Zydus Cadila launched new product for COPD patients in India.
2021
  • Zydus Cadila launched Trastuzumab Emtansine under brand Ujvira.
  • Cadila Healthcare received orphan drug designation for malaria treatment compound.
2022
  • Zydus Life received USFDA final approvals for Silodosin and Pregabalin.
  • Zydus Group had 338 approvals and filed over 431 ANDAs.
  • Zydus Life received final USFDA approval for Topiramate extended-release capsules.
  • Zydus Lifesciences' arm received EC approval for MoCD injection.
  • Received Pharma Company of the Year Award, Excellence in CSR, and 7th India Pharma CSR award.
2023
  • Zydus Lifesciences inked licensing pact with Daewoong Pharmaceutical.
  • Zydus Lifesciences received USFDA approval for Acyclovir Cream.
  • Sentynl Therapeutics completed asset transfer of CUTX-101 from Cyprium Therapeutics.
  • Zydus Lifesciences received 7th CSR Health Impact Award.
2024
  • Zydus Lifesciences received WHO prequalification for Typhoid Vi conjugate vaccine.
  • Zydus Lifesciences received Mexican regulatory approval for cancer treatment biosimilar.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
UBS PRINCIPAL CAPITAL ASIA LIMITEDSell67016641128.1130 Aug 2024

Read More

zydus lifesciences limited News

Zydus Lifesciences Senior VP Corporate Affairs Retires

Zydus Lifesciences Limited announces the superannuation of Mr. Manoj Kumar Kamra, Senior Vice President-Corporate Affairs, effective January 31, 2026, following regulatory disclosure requirements.

31 Jan 2026

stocks

Zydus Lifesciences Board Meet on Feb 9 for Q3 Results

Zydus Lifesciences Limited has scheduled its Board of Directors meeting for February 9, 2026, to consider and approve unaudited financial results for Q3FY26 ended December 31, 2025.

27 Jan 2026

co actions results

Zydus USFDA Inspection Concludes with 3 Observations

Zydus Lifesciences' Unit-2 manufacturing plant at Ankleswar completed USFDA inspection from January 19-23, 2026, receiving 3 observations with no data integrity issues reported.

23 Jan 2026

stocks

Zydus Lifesciences ESG Rating Revised to 84/100

S&P Global has revised Zydus Lifesciences' Corporate Sustainability Assessment ESG Score from 83/100 to 84/100 for 2025, marking an improvement in the company's sustainability performance.

20 Jan 2026

stocks

Zydus Completes Agenus Acquisition, Launches US Bio Unit

Zydus Lifesciences successfully completed acquisition of Agenus Inc.'s biologics facilities and equity stake, establishing Zylidac Bio LLC for US CDMO operations with regulatory approvals including CFIUS clearance.

15 Jan 2026

co actions results

Showing 15 of 58
Rows per page:

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800